 |
Diseases |  |
Trials |
|
Trials |  |
News |  |
- ORIC-944 / ORIC Pharma
Discovery of ORIC-944, a novel inhibitor of PRC2 with best-in-class properties for the treatment of prostate cancer (Ballroom 20 CD - Upper Level - Convention Center) - Mar 17, 2024 - Abstract #AACR2024AACR_9924;
Abstract is embargoed at this time.
- ORIC-944 / ORIC Pharma
ORIC-944, a potent and selective allosteric PRC2 inhibitor with best-in-class properties, demonstrates combination synergy with AR pathway inhibitors in prostate cancer models (Ballroom 6 DE - Upper Level - Convention Center) - Mar 5, 2024 - Abstract #AACR2024AACR_8825;
P1
RNA-seq analysis of transcriptional changes induced by ORIC-944 provided mechanistic insight into the role of PRC2 in prostate cancer lineage plasticity and combination response.These results position ORIC-944 as a best-in-class PRC2 inhibitor for evaluation in combination with ARPI in patients with metastatic prostate cancer. A phase 1b trial of ORIC-944 is ongoing (NCT05413421).
- ORIC-944 / ORIC Pharma
Biomarker strategy for a phase 1 study of ORIC-944, a potent and selective allosteric PRC2 inhibitor, in patients with metastatic prostate cancer (Section 18; Poster Board #14) - Mar 14, 2023 - Abstract #AACR2023AACR_5017;
P1
We previously reported strong tumor growth inhibition with ORIC-944 in enzalutamide-resistant 22Rv1 prostate cancer xenografts. This comprehensive biomarker strategy enables us to establish target engagement and capture exposure-dependent pharmacodynamics in the ongoing phase 1 study evaluating ORIC-944 as a best-in-class PRC2 inhibitor for the treatment of patients with advanced prostate cancer.
- || ORIC-944 / ORIC Pharma
Enrollment open, Metastases: Study of ORIC-944 in Patients With Metastatic Prostate Cancer (clinicaltrials.gov) - Jun 21, 2022
P1, N=42, Recruiting, Sponsor: ORIC Pharmaceuticals
This comprehensive biomarker strategy enables us to establish target engagement and capture exposure-dependent pharmacodynamics in the ongoing phase 1 study evaluating ORIC-944 as a best-in-class PRC2 inhibitor for the treatment of patients with advanced prostate cancer. Not yet recruiting --> Recruiting
- || ORIC-944 / ORIC Pharma
New P1 trial, Metastases: Study of ORIC-944 in Patients With Metastatic Prostate Cancer (clinicaltrials.gov) - Jun 9, 2022
P1, N=42, Not yet recruiting, Sponsor: ORIC Pharmaceuticals
- ORIC-944 / ORIC Pharma
[VIRTUAL] ORIC-944, a potent and selective allosteric PRC2 inhibitor, demonstrates robust in vivo activity in prostate cancer models () - Mar 11, 2021 - Abstract #AACR2021AACR_1954;
These in vivo studies established that effective single agent inhibition of PRC2 via EED results in decreased tumor cell growth in PRC2-dependent prostate cancer models.In summary, ORIC-944 is a potent, highly selective, allosteric, orally bioavailable PRC2 inhibitor via the EED subunit that represents a differentiated strategy to block PRC2 activity in selected cancers. We are developing ORIC-944 as a best-in-class PRC2 inhibitor for the treatment of patients with advanced prostate cancer and expect to file an IND in the second half of 2021.